Cover Image
市場調查報告書

PharmaPoint:偏頭痛 - EU5個國家的醫藥品的預測與市場分析

PharmaPoint: Migraine - 5EU Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 299712
出版日期 內容資訊 英文 149 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:偏頭痛 - EU5個國家的醫藥品的預測與市場分析 PharmaPoint: Migraine - 5EU Drug Forecast and Market Analysis to 2023
出版日期: 2014年03月31日 內容資訊: 英文 149 Pages
簡介

偏頭痛治療藥市場學名藥已呈現飽和狀態,上市的剩餘品牌藥除了慢性偏頭痛治療藥Botox,今後數年間將失去獨佔性。偏頭痛治療藥市場預測到2023年將擴大到37億美金,並以CAGR3.6%的速度成長。

本報告提供EU5個國家的偏頭痛治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),彙整SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
    • 預測
  • 症狀
    • 徵兆
    • 前驅症狀
    • 頭痛
    • 後發症狀

第4章 疾病的管理

  • 治療概要
    • 急性偏頭痛
    • 預防的偏頭痛
  • 法國
    • 診斷
    • 臨床診療
  • 德國
    • 診斷
    • 臨床診療
  • 義大利
    • 診斷
    • 臨床診療
  • 西班牙
    • 診斷
    • 臨床診療
  • 英國
    • 診斷
    • 臨床診療

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 領導品牌
    • Triptans
    • Imitrex (sumatriptan)
    • Zomig (zolmitriptan)
    • Amerge (naratriptan)
    • Maxalt (rizatriptan)
    • Axert (almotriptan)
    • Frova (frovatriptan)
    • Relpax (eletriptan)
    • Ergot Alkaloids
    • Beta Blockers
    • Anti-Epileptics
    • Antidepressants
    • Calcium Channel Antagonists
    • Botox (onabotulinum toxin A)

第6章 機會及未滿足需求

  • 概要
  • 未滿足需求的差距分析

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
    • RHB-103
    • Lasmiditan
    • MK-1602
    • RT-001
    • NXN-188

第8章 市場預測

  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第9章 附錄

圖表

目錄
Product Code: GDHC228CFR

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Each of the countries included in this report provide guidelines for the treatment of migraine. According to GlobalData's high-prescriber survey, the US, UK and Japan strongly adhere to their own national guidelines; however, the majority of the physicians from other EU countries (France, Germany, Italy and Spain) follow European guidelines such as the European Headache Federation (EHF) and European Federation of Neurological Societies (EFNS) guidelines.

Scope

  • Overview of Migraine including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU (the UK, France, Italy, Spain, Germany) from 2012-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US Migraine market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Migraine.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of drug performance.
  • Obtain sales forecast for drugs from 2012-2023 in 5EU (the UK, France, Italy, Spain, Germany).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms
    • 3.2.1. Premonitory Phase
    • 3.2.2. Aura Phase
    • 3.2.3. Headache Phase
    • 3.2.4. Postdrome Phase

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Acute Migraine Treatment
    • 4.1.2. Preventive Migraine Treatment
  • 4.2. France
    • 4.2.1. Diagnosis
    • 4.2.2. Clinical Practice
  • 4.3. Germany
    • 4.3.1. Diagnosis
    • 4.3.2. Clinical Practice
  • 4.4. Italy
    • 4.4.1. Diagnosis
    • 4.4.2. Clinical Practice
  • 4.5. Spain
    • 4.5.1. Diagnosis
    • 4.5.2. Clinical Practice
  • 4.6. UK
    • 4.6.1. Diagnosis
    • 4.6.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles- Major Brands
    • 5.3.1. Triptans
    • 5.3.2. Imitrex (sumatriptan)
    • 5.3.3. Zomig (zolmitriptan)
    • 5.3.4. Amerge (naratriptan)
    • 5.3.5. Maxalt (rizatriptan)
    • 5.3.6. Axert (almotriptan)
    • 5.3.7. Frova (frovatriptan)
    • 5.3.8. Relpax (eletriptan)
    • 5.3.9. Ergot Alkaloids
    • 5.3.10. Beta Blockers
    • 5.3.11. Anti-Epileptics
    • 5.3.12. Antidepressants
    • 5.3.13. Calcium Channel Antagonists
    • 5.3.14. Botox (onabotulinum toxin A)

6. Opportunity and Unmet Need

  • 6.1. Overview
    • 6.1.1. A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders
    • 6.1.2. Lack of Acute Therapies for Patients Unresponsive to Triptan Medication
    • 6.1.3. Lack of Diagnostic Tools Causes Misdiagnosis
    • 6.1.4. Physician Education
    • 6.1.5. Effective and Well-Tolerated Prophylactic Therapies
  • 6.2. Unmet Needs Gap Analysis
    • 6.2.1. Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication
    • 6.2.2. Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies
    • 6.2.3. Physician Education
    • 6.2.4. Diagnostic Tools

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising drugs in clinical development
    • 7.2.1. RHB-103
    • 7.2.2. Lasmiditan
    • 7.2.3. MK-1602
    • 7.2.4. RT-001
    • 7.2.5. NXN-188

8. Market Outlook

  • 8.1. France
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Driver and Barriers
  • 8.2. Germany
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Driver and Barriers
  • 8.3. Italy
    • 8.3.1. Forecast
    • 8.3.2. Key Events
    • 8.3.3. Driver and Barriers
  • 8.4. Spain
    • 8.4.1. Forecast
    • 8.4.2. Key Events
    • 8.4.3. Driver and Barriers
  • 8.5. United Kingdom
    • 8.5.1. Forecast
    • 8.5.2. Key Events
    • 8.5.3. Driver and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Migraine Patients
    • 9.4.2. Percent Drug-treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Survey of Prescribing Physicians
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Reviewer
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Classification of Migraine Subtypes
  • Table 2: Diagnostic Criteria for Migraine with Aura
  • Table 3: Diagnostic Criteria for Migraine without Aura
  • Table 4: Treatment Guidelines for Migraine
  • Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
  • Table 6: Product Profile - Triptans
  • Table 7: Triptans SWOT Analysis, 2013
  • Table 8: Product Profile - Ergot Alkaloids
  • Table 9: Ergot Alkaloids SWOT Analysis, 2013
  • Table 10: Product Profile - Beta Blockers
  • Table 11: Beta Blockers SWOT Analysis, 2013
  • Table 12: Product Profile - Anti-Epileptics
  • Table 13: Anti-Epileptics SWOT Analysis, 2013
  • Table 14: Product Profile - Antidepressants
  • Table 15: Antidepressants SWOT Analysis, 2013
  • Table 16: Product Profile-Calcium Channel Antagonists
  • Table 17: Calcium Channel Antagonists SWOT Analysis, 2013
  • Table 18: Product Profile - Botox
  • Table 19: Botox SWOT Analysis, 2013
  • Table 20: Overall Unmet Needs - Current Level of Attainment
  • Table 21: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 22: Migraine - Promising Late-Stage Pipeline, 2013
  • Table 23: Comparison of Therapeutic Classes in Development for Migraine, 2013
  • Table 24: Product Profile - RHB-103
  • Table 25: RHB-103 SWOT Analysis, 2013
  • Table 26: Product Profile - Lasmiditan
  • Table 27: Lasmiditan SWOT Analysis, 2013
  • Table 28: Product Profile - MK-1602
  • Table 29: MK-1602 SWOT Analysis, 2013
  • Table 30: Product Profile - RT-001
  • Table 31: RT-001 SWOT Analysis, 2013
  • Table 32: Product Profile - NXN-188
  • Table 33: NXN-188 SWOT Analysis, 2013
  • Table 34: Sales Forecasts ($m) for Migraine in France, 2012-2023
  • Table 35: Key Events Impacting Sales for Migraine in France, 2012-2023
  • Table 36: Migraine Market - Drivers and Barriers, 2012-2023
  • Table 37: Sales Forecasts ($m) for Migraine in Germany, 2012-2023
  • Table 38: Key Events Impacting Sales for Migraine in Germany, 2012-2023
  • Table 39: German Migraine Market - Drivers and Barriers, 2012-2023
  • Table 40: Sales Forecasts ($m) for Migraine in Italy, 2012-2023
  • Table 41: Key Events Impacting Sales for Migraine in Italy, 2012-2023
  • Table 42: Italian Migraine Market - Drivers and Barriers, 2012-2023
  • Table 43: Sales Forecasts ($m) for Migraine in Spain, 2012-2023
  • Table 44: Key Events Impacting Sales for Migraine in Spain, 2012-2023
  • Table 45: Spanish Migraine Market - Drivers and Barriers, 2012-2023
  • Table 46: Sales Forecasts ($m) for Migraine in the UK, 2012-2023
  • Table 47: Key Events Impacting Sales for Migraine in the UK, 2012-2023
  • Table 48: UK Migraine Market - Drivers and Barriers, 2012-2023
  • Table 49: Key Launch or Approval Dates
  • Table 50: Key Patent Expiries
  • Table 51: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Migraine Treatment Algorithm in the 7MM
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Migraine, 2012-2023
  • Figure 3: Sales for Migraine in France by Drug Class, 2012-2023
  • Figure 4: Sales for Migraine in Germany by Drug Class, 2012-2023
  • Figure 5: Sales for Migraine in Italy by Drug Class, 2012-2023
  • Figure 6: Sales for Migraine in Spain by Drug Class, 2012-2023
  • Figure 7: Sales for Migraine in the UK by Drug Class, 2012-2023
Back to Top